NCT04474119Unknown3 期
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of KN046 Combined With Platinum-containing Chemotherapy Versus Placebo Combined With Platinum-containing Chemotherapy in First Line Advanced Squamous Non-small Cell Lung Cancer Subjects (ENREACH-L-01)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 482
- 试验地点
- 1
- 主要终点
- Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging
研究概览
简要总结
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of KN046 plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin in subjects with advanced squamous NSCLC who have not previously received systemic treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has a histologically-confirmed or cytologically confirmed diagnosis of stage IV squamous NSCLC.
- •No known epidermal growth factor receptor (EGFR) mutations.
- •Has measurable disease.
- •Has not received prior systemic treatment for their advanced/metastatic NSCLC.
- •Can provide tumor tissue.
- •Has a life expectancy of at least 3 months.
- •Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.
- •Has adequate organ function
- •If female of childbearing potential, have a negative serum pregnancy test within 7 days prior to first trial treatment;
- •If female of childbearing potential or a male subject with a partner with childbearing potential, be willing to use a highly effective method of contraception (with a failure rate of less than 1.0% per year) from first study treatment to 24 weeks after completion of the trial treatment.
排除标准
- •Untreated active CNS metastasis or leptomeningeal metastasis.
- •Is currently participating and receiving an investigational drug or has participated in a study of an investigational drug within 4 weeks or within 5 times of half-life (no less than 2 weeks), whichever is shorter prior to the first dose of trial treatment;
- •Has received other anti-tumor treatment within 4 weeks or within 5 times of half-life (no less than 2 weeks), whichever is shorter prior to the first trial treatment;
- •Major surgery for any reason, except diagnostic biopsy, within 4 weeks of the first administration of trial treatment and/or if the subject has not fully recovered from the surgery within 4 weeks of the first administration of trial treatment;
- •Curative radiation within 3 months of the first dose of trial treatment. Radiation to more than 30% of the bone marrow or with a wide field of radiation should not be used within 4 weeks prior to the first administration of trial treatment;
- •Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment (with the exception of subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement doses, equivalent to < 10 mg prednisone daily, inhaled steroids and topical use of steroids);
- •Vaccination within 28 days of the first administration of trial treatment, except for administration of inactivated vaccines (e.g., inactivated influenza vaccines);
- •Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management;
- •History or current active autoimmune disease that might deteriorate when receiving an immunostimulatory agent
- •Previous malignant disease
- •History of uncontrolled intercurrent illness
- •Prior therapy with any antibody/drug targeting T cell coregulatory proteins
- •Known severe hypersensitivity reactions to antibody drug
- •Is pregnant or breastfeeding;
- •Other medical conditions that at the discretion of investigator interfere with the requirements of the trial in terms of safety or efficacy evaluation, or treatment compliance.
研究组 & 干预措施
Experimental arm
Experimental
KN046 plus Carboplatin and Paclitaxel
干预措施: KN046 (Drug)
Control arm
Placebo Comparator
Placebo plus Carboplatin and Paclitaxel
干预措施: KN046 placebo (Drug)
结局指标
主要结局
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging
时间窗: up to 2 years
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first.
Overall Survival (OS)
时间窗: up to 3 years
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up.
次要结局
- Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigators(up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary SarcoidosisPulmonary SarcoidosisNCT05415137aTyr Pharma, Inc.268
已完成
3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)Thyroid CancerNCT01321554Eisai Inc.392
进行中（未招募）
3 期
A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT06258148CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.465
招募中
3 期
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.Female Breast CancerAdvanced Breast CancerNCT05439499Ahon Pharmaceutical Co., Ltd.434
终止
3 期
A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid CancerDifferentiated Thyroid CancerNCT03602495Suzhou Zelgen Biopharmaceuticals Co.,Ltd204